Search
Elicio Therapeutics Inc
ELTXAdd to Watchlist
5.140USD
+1.230+31.46%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
98.10MMarket Cap
LossP/E TTM
More Details of Elicio Therapeutics Inc Company
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Elicio Therapeutics Inc Info
Ticker SymbolELTX
Company nameElicio Therapeutics Inc
IPO dateFeb 05, 2021
CEOConnelly (Robert)
Number of employees32
Security typeOrdinary Share
Fiscal year-endFeb 05
Address451 D Street, 5Th Floor
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02459
Phone18572090050
Websitehttps://elicio.com/
Ticker SymbolELTX
IPO dateFeb 05, 2021
CEOConnelly (Robert)
Company Executives of Elicio Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
-2799.46%
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
Dr. Julian Adams, Ph.D.
Dr. Julian Adams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Carol Ashe
Ms. Carol Ashe
Independent Director
Independent Director
--
--
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Ms. Yekaterina (Katie) Chudnovsky, J.D.
Independent Director
Independent Director
--
-100.00%
Dr. Robert R. Ruffolo, Jr.
Dr. Robert R. Ruffolo, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay R. Venkatesan, M.D.
Dr. Jay R. Venkatesan, M.D.
Director
Director
170.22K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
1.87K
--
Dr. Peter Demuth, Ph.D.
Dr. Peter Demuth, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
743.00
-2799.46%
Dr. Allen R. Nissenson, M.D.
Dr. Allen R. Nissenson, M.D.
Independent Director
Independent Director
--
--
Mr. Robert (Bob) Connelly
Mr. Robert (Bob) Connelly
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Dr. Christopher M. (Chris) Haqq, M.D., Ph.D.
Executive Vice President, Head - Research and Development, Chief Medical Officer
Executive Vice President, Head - Research and Development, Chief Medical Officer
--
--
FAQs
Who are the top five shareholders of Elicio Therapeutics Inc?
The top five shareholders of Elicio Therapeutics Inc are: Dr. Jay R. Venkatesan, M.D.
How many institutions hold shares of Elicio Therapeutics Inc (ELTX)?
As of 2026Q1, 75 institutions hold shares of Elicio Therapeutics Inc, with a combined market value of approximately 2.79M, accounting for 15.12% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -632315.00.